Ultragenyx Pharmaceutical (RARE) Free Cash Flow (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Free Cash Flow of -$198.0 million for Q1 2026, down 18.56% year-over-year from -$243.1 million in Q1 2025, and down 98.46% on a QoQ basis from -$99.8 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Free Cash Flow data on file, last reported at -$198.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 18.56% year-over-year to -$198.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$502.0 million (down 26.77% YoY) and the FY2025 annual result came in at -$471.0 million, down 11.88% from the prior year.
- Free Cash Flow eased to -$198.0 million in Q1 2026 per RARE's latest filing, from -$99.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$51.4 million in Q4 2023 and bottomed at -$198.0 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$99.8 million (2025), against an average of -$116.1 million.
- The widest annual swing landed in 2023, when Free Cash Flow slumped 66.53%; it then soared 52.79% in 2024.
- Tracing RARE's Free Cash Flow over 5 years: stood at -$87.9 million in 2022, then surged by 41.47% to -$51.4 million in 2023, then slumped by 54.53% to -$79.5 million in 2024, then decreased by 25.53% to -$99.8 million in 2025, then tumbled by 98.46% to -$198.0 million in 2026.
- Per Business Quant, the three latest RARE Free Cash Flow figures stand at -$198.0 million (Q1 2026), -$99.8 million (Q4 2025), and -$92.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -198.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -198.00 Mn |
| Mar 31, 2026 | -198.00 Mn |
| Dec 31, 2025 | -99.77 Mn |
| Dec 31, 2025 | -99.77 Mn |
| Sep 30, 2025 | -92.70 Mn |
| Sep 30, 2025 | -92.70 Mn |
| Jun 30, 2025 | -111.53 Mn |
| Jun 30, 2025 | -111.53 Mn |
| Mar 31, 2025 | -167.00 Mn |
| Mar 31, 2025 | -167.00 Mn |
| Dec 31, 2024 | -79.48 Mn |
| Dec 31, 2024 | -79.48 Mn |
| Sep 30, 2024 | -72.93 Mn |
| Sep 30, 2024 | -72.93 Mn |
| Jun 30, 2024 | -76.58 Mn |
| Jun 30, 2024 | -76.58 Mn |
| Mar 31, 2024 | -192.01 Mn |
| Mar 31, 2024 | -192.01 Mn |
| Dec 31, 2023 | -51.43 Mn |
| Dec 31, 2023 | -51.43 Mn |
| Sep 30, 2023 | -154.48 Mn |
| Sep 30, 2023 | -154.48 Mn |
| Jun 30, 2023 | -113.09 Mn |
| Jun 30, 2023 | -113.09 Mn |
| Mar 31, 2023 | -166.00 Mn |
| Mar 31, 2023 | -166.00 Mn |
| Dec 31, 2022 | -87.87 Mn |
| Dec 31, 2022 | -87.87 Mn |
| Sep 30, 2022 | -92.76 Mn |
| Sep 30, 2022 | -92.76 Mn |
| Jun 30, 2022 | -75.49 Mn |
| Jun 30, 2022 | -75.49 Mn |
| Mar 31, 2022 | -142.30 Mn |
| Mar 31, 2022 | -142.30 Mn |
| Dec 31, 2021 | -70.39 Mn |
| Dec 31, 2021 | -70.39 Mn |
| Sep 30, 2021 | -80.21 Mn |
| Sep 30, 2021 | -80.21 Mn |
| Jun 30, 2021 | -85.43 Mn |
| Jun 30, 2021 | -85.43 Mn |
| Mar 31, 2021 | -175.76 Mn |
| Mar 31, 2021 | -175.76 Mn |
| Dec 31, 2020 | -84.40 Mn |
| Dec 31, 2020 | -84.40 Mn |
| Sep 30, 2020 | -65.75 Mn |
| Sep 30, 2020 | -65.75 Mn |
| Jun 30, 2020 | 83.27 Mn |
| Jun 30, 2020 | 83.27 Mn |
| Mar 31, 2020 | -109.25 Mn |
| Mar 31, 2020 | -109.25 Mn |
| Dec 31, 2019 | -83.54 Mn |
| Dec 31, 2019 | -83.54 Mn |
| Sep 30, 2019 | -93.54 Mn |
| Sep 30, 2019 | -93.54 Mn |
| Jun 30, 2019 | -94.30 Mn |
| Jun 30, 2019 | -94.30 Mn |
| Mar 31, 2019 | -98.83 Mn |
| Mar 31, 2019 | -98.83 Mn |
| Dec 31, 2018 | -57.05 Mn |
| Dec 31, 2018 | -57.05 Mn |
| Sep 30, 2018 | -70.19 Mn |
| Sep 30, 2018 | -70.19 Mn |
| Jun 30, 2018 | -77.46 Mn |
| Jun 30, 2018 | -77.46 Mn |
| Mar 31, 2018 | -89.95 Mn |
| Mar 31, 2018 | -89.95 Mn |
| Dec 31, 2017 | -80.33 Mn |
| Dec 31, 2017 | -80.33 Mn |
| Sep 30, 2017 | -63.03 Mn |
| Sep 30, 2017 | -63.03 Mn |
| Jun 30, 2017 | -49.20 Mn |
| Jun 30, 2017 | -49.20 Mn |
| Mar 31, 2017 | -61.69 Mn |
| Mar 31, 2017 | -61.69 Mn |
| Dec 31, 2016 | -38.31 Mn |
| Dec 31, 2016 | -38.31 Mn |
| Sep 30, 2016 | -31.75 Mn |
| Sep 30, 2016 | -31.75 Mn |
| Jun 30, 2016 | -44.70 Mn |
| Jun 30, 2016 | -44.70 Mn |
| Mar 31, 2016 | -46.37 Mn |
| Mar 31, 2016 | -46.37 Mn |
| Dec 31, 2015 | -42.37 Mn |
| Dec 31, 2015 | -42.37 Mn |
| Sep 30, 2015 | -32.58 Mn |
| Sep 30, 2015 | -32.58 Mn |
| Jun 30, 2015 | -17.87 Mn |
| Jun 30, 2015 | -17.87 Mn |
| Mar 31, 2015 | -18.12 Mn |
| Mar 31, 2015 | -18.12 Mn |
| Dec 31, 2014 | -11.00 Mn |
| Dec 31, 2014 | -11.00 Mn |
| Sep 30, 2014 | -12.53 Mn |
| Sep 30, 2014 | -12.53 Mn |
| Jun 30, 2014 | -10.15 Mn |
| Jun 30, 2014 | -10.15 Mn |
| Mar 31, 2014 | -11.19 Mn |
| Mar 31, 2014 | -11.19 Mn |
| Dec 31, 2013 | -9.90 Mn |
| Dec 31, 2013 | -9.90 Mn |
| Sep 30, 2013 | -6.95 Mn |
| Sep 30, 2013 | -6.95 Mn |
| Jun 30, 2013 | -8.29 Mn |
| Jun 30, 2013 | -8.29 Mn |
| Mar 31, 2013 | -6.47 Mn |
| Mar 31, 2013 | -6.47 Mn |